Back to Journals » OncoTargets and Therapy » Volume 9

Review

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor

       
Total article views   HTML views PDF downloads Totals
10,122 Dovepress* 9,173+ 1,354 10,527
PubMed Central* 949 324 1,273
Totals 10,122 1,678 11,800
*Since 10 May 2016
+Since July 2016

View citations on PubMed Central and Google Scholar